Abstract
Introduction
Psoriasis is a highly divergent disease with many disease phenotypes, but there are currently no established biomarkers to predict the therapeutic outcomes of systemic treatments. With the introduction of biologic therapies during the last decade and with new treatments constantly emerging, there is a great need to validate biomarkers that have been reported to be associated with treatment response, and to introduce new biomarkers of possible clinical value.
Methods
In the current study, we aimed to investigate the association of psoriasis-related polymorphisms that have previously been reported to effect the anti-tumor necrosis factor alpha (anti-TNF-α) therapies (etanercept, adalimumab, and infliximab) and anti-interleukin-12/23 (anti-IL-12/23) biologic therapy (ustekinumab) in a Greek cohort of psoriasis patients.
Results
Rs10484554 in the HLA-C gene showed an association with a good response to anti-TNF-α agents but not to ustekinumab, while rs151823 and rs26653 in the ERAP1 gene showed associations with a good response to anti-IL-12/23 therapy.
Conclusion
This study is the first in the field of pharmacogenetics in Greek psoriasis patients. Further, larger studies are required to validate our findings and replicate them in various populations.
This is a preview of subscription content, log in via an institution to check access.
References
Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985–90.
Yin X, Low HQ, Wang L, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916.
Sun LD, Cheng H, Wang ZX, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet. 2010;42:1005–9.
Julia A, Tortosa R, Hernanz JM, et al. Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes. Hum Mol Genet. 2012;21:4549–57.
Masouri S, Stefanaki I, Kypreou KP, et al. Replication of risk variants for psoriasis in a Southern European case–control study: correlation with clinical subphenotypes. Br J Dermatol. 2015;173:552–4.
Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2012;16:29–34.
Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012;132:593–600.
Gallo E, Cabaleiro T, Román M, et al. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case–control study. Br J Dermatol. 2013;169:819–29.
Prieto-Pérez R, Cabaleiro T, Daudén E, et al. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 2013;13:297–305.
Prieto-Pérez R, Cabaleiro T, Daudén E, et al. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013;2013:613086.
Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.
Lysell J, Padyukov L, Kockum I, et al. Genetic association with ERAP1 in psoriasis is confined to disease onset after puberty and not dependent on HLA-C*06. J Invest Dermatol. 2013;133:411–7.
Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4:e1000041.
Galluzzo M, Boca AN, Botti E et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232. doi:10.1159/000441719.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors—Sofia Masouri, Irene Stefanaki, Giorgos Ntritsos, Katerina P. Kypreou, Eleni Drakaki, Evangelos Evangelou, Electra Nicolaidou, Alexandros John Stratigos, and Christina Antoniou—have no conflicts of interest that are directly relevant to the content of this study.
Funding
There was no funding for this study.
Ethical Approval and Informed Consent
The Scientific and Ethics Committee of Andreas Sygros Hospital (Athens, Greece) approved the research protocol for this study (ethics approval number 3049). All participants gave written informed consent for their participation in the study.
Additional information
S. Masouri and I. Stefanaki equally contributed to the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Masouri, S., Stefanaki, I., Ntritsos, G. et al. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents. Mol Diagn Ther 20, 221–225 (2016). https://doi.org/10.1007/s40291-016-0198-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-016-0198-z